144 results about "Corneal epithelial cell" patented technology

A material that can be applied as implants designed to artificially replace or augment the cornea, such as an artificial cornea, corneal onlay, or corneal inlay (intrastromal lens) is provided. The artificial corneal implant has a double network hydrogel with a first network interpenetrated with a second network. The first network and the second network are based on biocompatible polymers. At least one of the network polymers is based on a hydrophilic polymer. The artificial cornea or implant has epithelialization promoting biomolecules that are covalently linked to the surface of the double network hydrogel using an azide-active-ester chemical linker. Corneal epithelial cells or cornea-derived cells are adhered to the biomolecules. The double network has a physiologic diffusion coefficient to allow passage of nutrients to the adhered cells.

The present invention relates to: a method for inducing differentiation into an epithelial progenitor cell/stem cell population or a corneal epithelial cell population by culturing, under particular conditions, induced pluripotent stem cells induced from mammalian somatic cells or undifferentiated stem cells; an epithelial progenitor cell/stem cell population or a corneal epithelial cell population obtained by the method; and a cell preparation for the treatment of epithelial disease and a cell sheet, which are prepared using these cell populations.

The present invention relates to the use of lacritin, and fragments, derivatives, and homologs thereof, and nucleic acid sequences encoding that protein. The invention relates to the use of lacritin as a growth factor human corneal epithelial cells and other select epithelial cells. The invention also relates to the use of lacritin in promoting ocular cell survival in response to an insult or injury, in protecting against ocular inflammation, and in promoting ocular wound repair.

The invention discloses a preparation method for artificial corneas. The preparation method comprises the following steps of (1) collecting age-appropriate pig eyeballs; (2) scraping corneal epithelial cells and corneal endothelial cells of the pig eyeballs, reserving bowman layers, preparing lamellar corneas by using a lamellar blade, and drilling size-specific corneal slices; (3) putting the corneal slices obtained in step (2) in liquid nitrogen for 8-35 minutes, slowly rewarming the corneal slices to room temperature under normal temperature and normal pressure after the corneal slices are taken out, repeating the operation for 4-12 times; (4) putting the corneal slices which are subjected to freezing-thawing treatment in step (3) in normal saline for carrying out ultrasonic cleaning, wherein the ultrasonic working frequency is 20-250 kHz, and the ultrasonic time is 15-65 minutes; (5) putting the corneal slices which are subjected to ultrasonic treatment in a buffer system, carrying out enzymolysis on DNA (Deoxyribose Nucleic Acid) of corneal stromal cells by using endonuclease, and obtaining the artificial corneas. According to the artificial corneas prepared by the preparation method disclosed by the invention, gaps between natural collagen fibers of the artificial corneas are beneficial for inducing the growth of the corneal cells and the growth of nerve fibers of an acceptor and promoting the repairing and the reconstructing of corneas of a donor.

The invention provides a corneal contact lens nursing composition containing mycose, and also relates to the compositions of the type. The composition comprises the following components in weight percent: 0.001-8% of mycose, 0.01-3% of isotonic regulator, 0.001-4% of buffering agent, 0.01-3% of lubricating moisturizing agent, 0.001-1% of complexing agent, 0.01-1% of surface active agent and 0.00001-0.15% of antimicrobial agent. The invention is used for the storage, sterilization, cleaning, lubrication, moisture preservation and dry resistance of the lens of the corneal contact lens and for the rehumidification of the lens, can relieve the dryness and acid bilges of the eyes, reduce the death rate of the corneal epithelial cell in a dry environment, and improve the restoration of the corneal epithelial and intradermal cells.

The invention discloses a 3D model constructed in vitro by means of a serum-free culture medium as well as a construction method of the 3D model and relates to the technical field of biological materials in tissue engineering. Due to selection variety of seed cells and good in-vitro construction repeatability, industrial preparation of the 3D model can be realized. The model is an in-vitro model formed by primary corneal epithelial cells subjected to tissue isolation, limbal stem cells, immortalized corneal epithelial cells, primary oral epithelial cells or oral mucosa squamous cancer cell lines TR146 subjected to in-vitro amplification and stratified through the serum-free culture medium with an undersurface-gas-liquid surface staged culture method.

The invention relates to a method for constructing a human corneal epithelial cell system. The construction method comprises the following steps of: disinfecting cornea, digesting the cornea, taking off corneal epithelium with a front elastic layer, cutting the corneal epithelium into small tissue blocks, flatly attaching the tissue blocks to the bottom of culture holes downwards, adding culture solution into a carbon dioxide culture box, and performing plate-attaching culture at the temperature of 37 DEG C, changing the culture solution during culturing, performing subculture when the cells grow into a single layer, and presently, completing the construction of the human corneal epithelial cell system above 60 generations, wherein the culture solution contains 20 percent of fetal calf serum, 0.002 to 0.004 percent of human epidermic cell growth factor, 0.001 to 0.002 percent of human alkali fibroblast growth factor, 0.04 to 0.1 percent of carboxymethyl chito-oligosaccharide, 0.025 to0.1 percent of DMEM/F12 culture solution of chondroitin sulfate, and 0.008 to 0.01 percent of IV type collagen. In the construction method, the non-transfection human corneal epithelial cell system is successfully constructed by utilizing the human corneal epithelial tissues, and the constructed cell system can realize continuous transfer of culture, and a great number of human corneal epithelialcells are provided.

An artificial cornea is fabricated by separately culturing live stromal cells, live corneal endothelial cells (CECs) and live corneal epithelial cells (CEpCs), and 3D bioprinting separate stromal, CEC and CEpC layers to encapsulate the cells into separate hydrogel nanomeshes. The CEC layer is attached to a first side of the stromal layer and the CEpC layer to a second side of the stromal layer to define the artificial cornea.

The invention relates to the field of cell culture, in particular relates to letilla striata polysaccharide hydrogel, a culture medium and application thereof as well as a method of inducing differentiation of umbilical cord mesenchymal stem cells (hUC-MSCs) to corneal epithelial cells. The method comprises the steps of sulfating letilla striata polysaccharide and then crosslinking with Epsilon-polylysine carrying polyfunctional groups to prepare the polysaccharide hydrogel. The letilla striata polysaccharide hydrogel is of a semi-transparent membrane, has good porosities, and is suitable for the growth and the differentiation of cells. The experiment shows that by taking the letilla striata polysaccharide hydrogel provided by the invention as a scaffold, after the hUC-MSCs and amniotic epithelial cells are subjected to co-culture for 7 days, the differentiation rate of the hUC-MSCs can be up to 31.96%. The differentiation rate (p is less than 0.01) is obviously superior to that of a contrasting example which does not adopt the hydrogel scaffold. In addition, the hydrogel provided by the invention can promote the cells to grow vigorously, and shorten the induction time.

A material that can be applied as implants designed to artificially replace or augment the cornea, such as an artificial cornea, corneal onlay, or corneal inlay (intrastromal lens) is provided. The artificial corneal implant has a double network hydrogel with a first network interpenetrated with a second network. The first network and the second network are based on biocompatible polymers. At least one of the network polymers is based on a hydrophilic polymer. The artificial cornea or implant has epithelialization promoting biomolecules that are covalently linked to the surface of the double network hydrogel using an azide-active-ester chemical linker. Corneal epithelial cells or cornea-derived cells are adhered to the biomolecules. The double network has a physiologic diffusion coefficient to allow passage of nutrients to the adhered cells.

A major object of the present invention is to provide a method for inducing cell differentiation into corneal epithelial stem cells and/or corneal epithelial cells, for the easy production of a corneal epithelial cell sheet having superior safety in view of the possibility of vascularization and the like occurring. A method for inducing differentiation of a pluripotent stem cell into a corneal epithelial stem cell and/or a corneal epithelial cell, the method comprising the step of culturing a pluripotent stem cell in the presence of a stromal cell or an amnion-derived factor.

The invention relates to the field of stem cell culture, in particular to a culture medium and method for inducing differentiation of umbilical cord mesenchymal stem cells to corneal epithelial cells. An epidermal growth factor and insulin are added into a basic culture solution, so that the percentage of differentiation of hUC-MSCs to the corneal epithelial cells is increased. Moreover, the culture solution does not contain heterogenous serum, so that the risk is lowered. According to the method provided by the invention, the umbilical cord mesenchymal stem cells and amniotic epithelial cells are co-cultured, so that the differentiation percentage can be increased remarkably, and the required culture period is short. The adopted umbilical cord mesenchymal stem cells are derived from umbilical cords and placentas, so that the source is wide, and legal and ethical limitations are avoided.

The invention discloses a preparation method for temperature sensing cornea epithelial cell culture material and application. The method is as follows: combining nitrine-aniline derivative of N- isopropyl acrylamide/acrylic acid, and then fixing the nitrine aniline derivative of N-isopropyl acrylamide/acrylic acid on a polystyrene board used for tissue culture by a UV-light chemical graft method, thus obtaining the culture material. The invention also discloses the application of the temperature sensing cornea epithelial cell culture material in culturing human corneal epithelial cells. The temperature sensing cornea epithelial cell culture material prepared by the preparation method has good plasticity and biocompatibility, can support the good growth of the cornea epithelial cells, does not cause inflammatory reaction or cell functional damage, and has good clinical application prospect.

The invention discloses a tissue engineered cornea. The tissue engineered cornea comprises at least three amnion tissue layers, wherein corneal stromal cells are grown between two adjacent amnion tissue layers, extracellular matrixes which are secreted by the corneal stromal cells and contain keratocan, lumican, I type collagen and V type collagen are also contained, and the extracellular matrixesare regularly arranged, so that a tissue structure similar to corneal stroma is formed. Corneal epithelial cells and corneal endothelial cells are respectively inoculated on the upper surface and thelower surface of the structure, so that a total cornea is formed. Surface collagenous fibers of the amnion tissue layers are regularly arranged, are parallel to each other and are transversally intersected and closely arranged to form a fiber sheet, so that the corneal stromal cells and the extracellular matrixes secreted by the corneal stromal cells are guided to be regularly arranged; and at least three amnion tissue layers have the characteristic of inhibiting fibrosis, so that the characteristics of the corneal stromal cells are maintained, and differentiation of the corneal stromal cellsto fibroblasts is inhibited.

The present invention relates to a novel lacrimal gland protein (designated lacritin) and the nucleic acid sequences encoding that protein. Lacritin has activity as a growth factor on both human corneal epithelial cells and on the lacrimal acinar cells that produce it. Accordingly, one embodiment of the present invention is directed to the use of lacritin to treat Dry Eye and other disorders requiring the wetting of the eye.

The invention discloses applications of human placenta peptide in preparing drugs for treating simple keratitis, dry eye syndrome, corneal epithelium erosion, corneal alkali burn, various keratititides, LASIK corneal laser surgery and other ocular surface diseases. The experiment proves that the human placenta peptide can increase the tear liquid secretion amount of a dry eye model of New Zealand white rabbits, promote the repairation of corneal epithelium cell damage, increase the quantity of conjunctiva goblet cells, has no stimulation to eyes, and has therapeutic effect on the dry eye model of the New Zealand white rabbit with obvious curative effect, thus the human placenta peptide can be used for treating the dry eye syndrome, the corneal epithelium erosion, corneal epithelium defect, the corneal alkali burn, keratitis and the LASIK corneal laser surgery and the other ocular surface diseases.

A corneal contact lens nursing composition containing trehalose quaternary ammonium salt is provided; the corneal contact lens nursing composition is characterized by consisting of the following components in percentage by weight: 0.001-2% of trehalose quaternary ammonium salt, 0.01-2% of isotonic regulator, 0.05-2% of surfactant, 0.01-1% of complexing agent, 0.01-3% of buffer, 0.00001-1% of anti-microorganism compound and 89-99.91899% of water. The composition provided by the invention has corneal contact lens storing, sterilizing, cleaning, lubricating, hydrating and anti-drying functions and is very effective for relieving dryness and stiffness of eyes; by adopting the composition, the death rate of corneal epithelial cells under a dry condition is reduced and the repairing of corneal epithelial cells and endothelial cells is prompted. The kill rate of each composition to escherichia coli, pseudomonas aeruginosa and staphylococcus aureus is greater than 99.9% and the kill rate to candida albica and solanaceae fusarium is greater than 90.0%.

Provision of an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, and a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like.

A preparation containing [3-[2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazol-6-yl]oxyacetic acid, [4-[3-[2-(4-trifluoromethyl)phenyl-4-isopropyl-5-thiazolyl]propionyl]-2-methylphenoxy]acetic acid or [4-[3-[2-(2-hydroxy-4-chlorophenyl)-5-isopropyl-4-oxazolyl]propionyl]-2-methylphenoxy]acetic acid, or a pharmacologically acceptable salt thereof as an active ingredient is used as an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, as well as a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like.

The invention discloses a method for large-scale preparation of high-purity unsaturated hyaluronic acid disaccharide. The method adopts two-step enzymolysis and two-step purification, and specificallyincludes the steps of: firstly, carrying out enzymolysis on macromolecular hyaluronic acid or salt thereof by hyaluronidase, purifying the obtained product with a low organic solvent multiple to obtain low-molecular-weight hyaluronic acid or salt thereof with high purity, further performing thorough enzymolysis on the low-molecular-weight hyaluronic acid or salt thereof, and purifying the obtained product with a high organic solvent multiple to obtain the high-purity unsaturated hyaluronic acid disaccharide. The method has simple technological process operation, mild conditions, high production efficiency, low energy consumption, and is suitable for large-scale industrial production. The obtained product has high purity and low cytotoxicity, has the characteristic of promoting the proliferation of human umbilical vein endothelial cells and human corneal epithelial cells, can be used as a standard substance for content and purity detection of hyaluronic acid and related products thereof, and also has wide application prospect in the field of medicines.